About Hibergene diagnostics
HiberGene Diagnostics: Revolutionizing Molecular Diagnostic Testing for Human Infectious Diseases
HiberGene Diagnostics is a leading molecular diagnostic company that specializes in the development, manufacturing, and marketing of innovative diagnostic tests for human infectious diseases. The company was founded in 2009 by Dr. Brendan Farrell and Dr. Seamus Gorman with the aim of providing accurate and reliable diagnostic solutions to healthcare professionals worldwide.
With its headquarters located in Dublin, Ireland, HiberGene Diagnostics has established itself as a global leader in the field of molecular diagnostics. The company's cutting-edge technology enables rapid and accurate detection of infectious diseases such as tuberculosis (TB), meningitis, sepsis, influenza, and COVID-19.
HiberGene's proprietary technology is based on loop-mediated isothermal amplification (LAMP) which allows for highly sensitive and specific detection of nucleic acid targets without the need for complex instrumentation or specialized training. This makes HiberGene's tests ideal for use in resource-limited settings where traditional laboratory-based testing may not be feasible.
One of HiberGene's flagship products is HG Meningococcus which is a rapid molecular test designed to detect Neisseria meningitidis - the bacterium responsible for meningococcal disease - directly from clinical specimens such as cerebrospinal fluid (CSF) or blood culture bottles. HG Meningococcus provides results within an hour compared to traditional methods which can take up to several days.
Another key product from HiberGene is HG Group B Streptococcus (GBS) which detects GBS - a common cause of neonatal sepsis - from vaginal/rectal swabs taken during pregnancy. Early identification of GBS colonization allows healthcare providers to administer prophylactic antibiotics during labor thereby reducing the risk of transmission to newborns.
In response to the ongoing COVID-19 pandemic, HiberGene has developed HG Swift SARS-CoV-2 which is a rapid molecular test for the detection of SARS-CoV-2 - the virus responsible for COVID-19. HG Swift SARS-CoV-2 provides results within 60 minutes and has been validated on multiple sample types including nasopharyngeal swabs, saliva, and sputum.
HiberGene's commitment to innovation and excellence has earned the company numerous accolades including the Frost & Sullivan 2020 European Molecular Diagnostics Company of the Year Award. The company's products are used in over 60 countries worldwide with a strong presence in Europe, Africa, Asia-Pacific, and Latin America.
In addition to its core business of developing diagnostic tests, HiberGene also offers training and support services to healthcare professionals to ensure optimal use of its products. The company's team of experienced scientists and technical experts are always on hand to provide guidance on test selection, interpretation of results, troubleshooting issues, and more.
Overall, HiberGene Diagnostics is a game-changer in the field of molecular diagnostics with its innovative technology that enables rapid and accurate detection of infectious diseases. With a strong focus on customer satisfaction and quality assurance, HiberGene is poised for continued growth as it expands its product portfolio into new areas such as antimicrobial resistance testing.